| Nicole Reaves, MS, OTR/L, CHT | |
|
5630 E Santa Ana Canyon Rd Ste 105, Anaheim, CA 92807 | |
| (714) 282-7701 | |
| Not Available |
| Full Name | Nicole Reaves |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 10 Years |
| Location | 5630 E Santa Ana Canyon Rd Ste 105, Anaheim, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235544354 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 14414 (California) | Secondary |
| 225XH1200X | Occupational Therapist - Hand | 14414 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Magnolia Physical Therapy Inc | 0840193561 | 6 |
| Laguna Beach Rehab, Inc. | 4688686538 | 11 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
| Provider Name | California Rehab And Sports Therapy |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1386696409 PECOS PAC ID: 6709788896 Enrollment ID: O20040120001115 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
| Provider Name | Magnolia Physical Therapy Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1982642336 PECOS PAC ID: 0840193561 Enrollment ID: O20040129001233 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
| Provider Name | Hands On Rehab, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1538174925 PECOS PAC ID: 1658334107 Enrollment ID: O20041105000894 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
| Provider Name | Hands On Hands Rehabilitation Center, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1821183070 PECOS PAC ID: 5991731655 Enrollment ID: O20050713000991 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
| Provider Name | Laguna Beach Rehab, Inc. |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1164466785 PECOS PAC ID: 4688686538 Enrollment ID: O20060615000176 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
| Provider Name | Hands On Rehab Eastbluff Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1356589816 PECOS PAC ID: 2264561257 Enrollment ID: O20100601000598 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Reaves, MS, OTR/L, CHT 200 Newport Center Dr Ste 213, Newport Beach, CA 92660-7503 Ph: (949) 644-1322 | Nicole Reaves, MS, OTR/L, CHT 5630 E Santa Ana Canyon Rd Ste 105, Anaheim, CA 92807 Ph: (714) 282-7701 |
News Archive
Two years ago, Britons were outraged when U.S. politicians like Sarah Palin, in the debate over health care reform, turned this country's National Health Service into a public whipping boy, denouncing it as "evil," "Orwellian" and generally the enemy of everything good and true.
In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.
The Atlanta-Journal Constitution recently published an editorial and an opinion piece that addressed issues related to the CDC cash awards process.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
The overall mortality in patients suffering non-neonatal tetanus is high. Efforts to reduce mortality in one sub-Saharan African intensive care unit by implementing a standard tetanus protocol did little to change mortality rates, although they shifted causes of deaths, researchers have now reported in PLOS Neglected Tropical Diseases.
› Verified 6 days ago
Riva Nandi, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1360 S Anaheim Blvd, Anaheim, CA 92805 Phone: 714-542-1234 | |
Macy Burr, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 140 S Chaparral Ct, Suite 150, Anaheim, CA 92808 Phone: 206-240-8451 | |
Alicia Stearns, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 160 S Old Springs Rd Ste 150, Anaheim, CA 92808 Phone: 949-273-6503 | |
Bethany Kimi Kalani Tomokiyo, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 140 S Chaparral Ct Ste 150, Anaheim, CA 92808 Phone: 714-794-5889 | |
Natalie Chu, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 217 W Cerritos Ave, Anaheim, CA 92805 Phone: 714-533-1230 Fax: 714-533-1232 | |
Karen Ngo, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2425 W Greenacre Ave, Anaheim, CA 92801 Phone: 714-417-4027 | |
Sepanta Yousefian, OTD, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 401 N Brookhurst St Ste 100, Anaheim, CA 92801 Phone: 714-563-2318 |